458 related articles for article (PubMed ID: 22121130)
1. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction.
Smolen JS; Avila JC; Aletaha D
Ann Rheum Dis; 2012 May; 71(5):687-93. PubMed ID: 22121130
[TBL] [Abstract][Full Text] [Related]
2. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients.
Aletaha D; Alasti F; Smolen JS
Ann Rheum Dis; 2013 Jan; 72(1):7-12. PubMed ID: 22915619
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials.
Verhoeven MMA; Tekstra J; Jacobs JWG; Bijlsma JWJ; van Laar JM; Pethö-Schramm A; Borm MEA; Lafeber FPJ; Welsing PMJ
Arthritis Care Res (Hoboken); 2022 Jun; 74(6):889-895. PubMed ID: 33253497
[TBL] [Abstract][Full Text] [Related]
4. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
[TBL] [Abstract][Full Text] [Related]
6. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Kelman A; Dimonaco S; Mitchell N
Ann Rheum Dis; 2016 Jun; 75(6):1081-91. PubMed ID: 26511996
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
[TBL] [Abstract][Full Text] [Related]
10. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW
Ann Rheum Dis; 2013 Jan; 72(1):43-50. PubMed ID: 22562983
[TBL] [Abstract][Full Text] [Related]
11. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.
Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; van Laar JM; Lafeber FPJG; Bijlsma JWJ
Rheumatology (Oxford); 2018 Feb; 57(2):309-317. PubMed ID: 29095992
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
Navarro-Millán I; Singh JA; Curtis JR
Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
15. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.
Huizinga TW; Conaghan PG; Martin-Mola E; Schett G; Amital H; Xavier RM; Troum O; Aassi M; Bernasconi C; Dougados M
Ann Rheum Dis; 2015 Jan; 74(1):35-43. PubMed ID: 25169728
[TBL] [Abstract][Full Text] [Related]
16. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS
Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
[TBL] [Abstract][Full Text] [Related]
18. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab--preliminary data.
Hama M; Uehara T; Takase K; Ihata A; Ueda A; Takeno M; Shizukuishi K; Tateishi U; Ishigatsubo Y
Rheumatol Int; 2012 May; 32(5):1327-33. PubMed ID: 21293859
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial.
Kremer JM; Blanco R; Halland AM; Brzosko M; Burgos-Vargas R; Mela CM; Rowell L; Fleischmann RM
Clin Exp Rheumatol; 2016; 34(4):625-33. PubMed ID: 27087059
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
